No problem Wayne. Thanks for your post.
You wrote;
The outline of initial findings by Dr Mondello relates to the first cohort of the Phase II Intrepid2566 trial. Enrolment for the first cohort, however, was completed in May 2011. Its fascinating why the findings are being presented at this stage. Would it really take more than two years to analyse the data?
Perhaps it's been a work in progress?? Do you think it may also have something to do with evaluating the drug's possible molecular mechanisms? Note re outline, the markers are also being evaluated to identify possible molecular mechanisms of the drug. I found this fascinating.
Also have another read of the Arrowhead presentation...
http://www.neurenpharma.com/ssl/cms/files_cms/Arrowhead%20TBI%20Conference%20NNZ2566%20Presentation.pdf
Tony
- Forums
- ASX - By Stock
- NEU
- intrepid2566
NEU
neuren pharmaceuticals limited
Add to My Watchlist
3.17%
!
$14.63

intrepid2566, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.63 |
Change
0.450(3.17%) |
Mkt cap ! $1.823B |
Open | High | Low | Value | Volume |
$14.36 | $14.75 | $14.36 | $8.589M | 588.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
19 | 1098 | $14.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.63 | 105 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 751 | 14.600 |
9 | 748 | 14.590 |
5 | 1322 | 14.580 |
5 | 1379 | 14.570 |
6 | 1270 | 14.560 |
Price($) | Vol. | No. |
---|---|---|
14.620 | 3292 | 18 |
14.630 | 1236 | 8 |
14.640 | 2628 | 7 |
14.650 | 6618 | 10 |
14.660 | 1335 | 6 |
Last trade - 15.38pm 10/07/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |